Very High Gross Margin And Recent Net ProfitA ~97% gross margin and a return to net profitability indicate strong unit economics or high-value products with low variable costs. Over 2–6 months this supports margin sustainability and profitability leverage if revenue stabilizes, improving long-term cash conversion potential.

Debt-free Balance Sheet With Sizable EquityEliminating debt materially lowers financial risk and interest burden, giving operational flexibility. A large equity base relative to assets provides a capital cushion to fund R&D, trials or commercialization without immediate refinancing, strengthening resilience over several months.

Improving Return On EquityROE turning positive signals the company is beginning to generate returns on shareholder capital after prior losses. This improvement, paired with strong margins and equity, suggests foundational progress toward durable profitability if operational issues are addressed.

Bears Say

Persistent Negative Operating And Free Cash FlowConsistent cash outflows mean the company is not self-funding operations despite net income. Over the medium term this creates financing dependence, risk of dilution or reduced investment capability, and constrains ability to scale or absorb setbacks without new capital.

Declining Revenue TrendTop-line contraction reduces operating leverage and makes high gross margins harder to exploit. A declining revenue trend over months signals market adoption or demand challenges that can limit sustainable growth and magnify the impact of any fixed costs or R&D spending.

Operating-level Performance (EBIT) Remains NegativeNegative EBIT implies core business operations are not yet profitable and net income may reflect one-offs or non-operating items. Structural improvement requires operating profitability to ensure earnings durability and genuine cash generation beyond accounting gains.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥868.00 and its highest was ¥3310.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥22.54B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is May 07, 2026 which is in 80 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on Feb 13, 2026. The company reported -¥5.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.21.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,250,100 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥5.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.626%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.